{
    "clinical_study": {
        "@rank": "131063", 
        "arm_group": [
            {
                "arm_group_label": "PDI-320", 
                "arm_group_type": "Experimental", 
                "description": "Foam, twice daily for up to 12 weeks"
            }, 
            {
                "arm_group_label": "PDI-320 Monad #1", 
                "arm_group_type": "Experimental", 
                "description": "Foam, twice daily for up to 12 weeks"
            }, 
            {
                "arm_group_label": "PDI-320 Monad #2", 
                "arm_group_type": "Experimental", 
                "description": "Foam, twice daily for up to 12 weeks"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Foam, twice daily for up to 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This 4-arm Phase 2 vehicle-controlled study is designed to assess the safety and efficacy of\n      PDI-320, and the individual components, in adult subjects with rosacea."
        }, 
        "brief_title": "An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rosacea", 
        "condition_browse": {
            "mesh_term": "Rosacea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has moderate to severe papulopustular rosacea and at least mild  erythema and\n             mild telangiectasia.\n\n          -  Subject is willing and able to apply the test article(s) as directed, comply with\n             study instructions and commit to all follow-up visits for the duration of the study.\n\n          -  If subject is a woman of childbearing potential, she must have a negative urine\n             pregnancy test and agree to use an effective form of birth control for the duration\n             of the study.\n\n        Exclusion Criteria:\n\n          -  Subject is pregnant, lactating or is planning to become pregnant during the study.\n\n          -  Subject has any other active dermatological condition on the face that may interfere\n             with the conduct of the study.\n\n          -  Subject has used systemic immunosuppressants within 30 days prior to study start.\n\n          -  Subject has used systemic retinoids within 6 months prior to study start.\n\n          -  Subject has used any topical rosacea therapy within 14 days prior to study start.\n\n          -  Subject has had laser or light therapy on the face within 3 months of study start.\n\n          -  Subject is currently enrolled in an investigational drug or device study.\n\n          -  Subject has used an investigational drug or investigational device treatment within\n             30 days prior to first application of the test article.\n\n          -  Subject has used vasodilators or adrenergic blocking agents within 6 weeks of study\n             start (except subjects on stable dose for greater than 3 months).\n\n          -  Subject has active ocular rosacea and/or blepharitis/meibomianitis requiring\n             treatment by an ophthalmologist.\n\n          -  Subject has previously failed to have improvement of rosacea with appropriate use of\n             systemic tetracycline family of antibiotics or use of the components of PDI-320."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828177", 
            "org_study_id": "172-7451-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "PDI-320", 
                "intervention_name": "PDI-320", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PDI-320 Monad #1", 
                "intervention_name": "PDI-320 Monad #1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PDI-320 Monad #2", 
                "intervention_name": "PDI-320 Monad #2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PreCision", 
            "PDI-320", 
            "Foam"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Therapeutics Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico"
                    }, 
                    "name": "Academic Dermatology Associates"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicenter Randomized Evaluator-Blinded Vehicle-Controlled Parallel Group Evaluation of Twice Daily PDI-320 in Comparison to Its Monads in Adults With Rosacea", 
        "overall_official": {
            "affiliation": "Therapeutics, Inc.", 
            "last_name": "Syd Dromgoole, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "IGA Score Success Rate is defined as the percentage of subjects who achieve \"Clear\" (score = 0) or \"Almost Clear\" (score = 1) and have at least a 2-grade improvement on the IGA score at the End of Treatment.  IGA score is used to evaluate the overall severity of rosacea using a 5-point scale from 0 (clear) to 4 (severe).", 
                "measure": "Treatment \"Success Rate\" based on change in Investigator's Global Assessment (IGA)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and End of Treatment (up to 12 weeks)"
            }, 
            {
                "description": "Inflammatory lesions include papules and pustules on the face, and are counted by study personnel.", 
                "measure": "Absolute change in inflammatory lesion count", 
                "safety_issue": "No", 
                "time_frame": "Baseline and End of Treatment (up to 12 weeks)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828177"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "IGA Score Success Rate is the same as defined in the Primary Outcome Measures.", 
                "measure": "Treatment \"Success Rate\" based on change in IGA (interim time points)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4 and Week 8"
            }, 
            {
                "description": "Inflammatory lesions include papules and pustules on the face, and are counted by study personnel.", 
                "measure": "Absolute change in inflammatory lesion count (interim time points)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4 and Week 8"
            }, 
            {
                "description": "The investigator will assess the erythema (skin redness) on the entire face, using a grading scale from 0 (none) to 4 (very severe)", 
                "measure": "Change in erythema severity", 
                "safety_issue": "No", 
                "time_frame": "Baseline and End of Treatment (up to 12 weeks)"
            }, 
            {
                "description": "The investigator will assess telangiectasia (small dilated blood vessels near the surface of the skin) on the face, using a grading scale of 0 (none) to 3 (severe).", 
                "measure": "Change in telangiectasia severity", 
                "safety_issue": "No", 
                "time_frame": "Baseline and End of Treatment (up to 12 weeks)"
            }
        ], 
        "source": "PreCision Dermatology, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PreCision Dermatology, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}